SCHEMBL15041769

SCHEMBL15041769

N#Cc1cc2cnc(Nc3ccc(C4=CCNCC4)cc3)nc2n(Cc2nccnc2-c2nccs2)c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 4/20 0.38
CDK6 Q00534 4/20 0.38
NUAK1 O60285 3/20 0.38
CDK1 P06493 3/20 0.38
PIK3CD O00329 1/20 0.38
PRKAB2 O43741 1/20 0.38
CCNT1 O60563 1/20 0.38
ABL1 P00519 1/20 0.38
FYN P06241 1/20 0.38
CSF1R P07333 1/20 0.38
RET P07949 1/20 0.38
PDGFRB P09619 1/20 0.38
FGFR1 P11362 1/20 0.38
CCNB1 P14635 1/20 0.38
CCNA2 P20248 1/20 0.38
CCND1 P24385 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
MARK3 P27448 1/20 0.38
FLT3 P36888 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034962 0.93 CDK4 (0.36) CDK4CDK6FGFR1CCNA2CCND1
SCHEMBL15036198 0.77 CDK4 (0.39) CDK4CDK6FGFR1CCNA2CCND1
SCHEMBL15041752 0.76 CDK4 (0.37) CDK4CDK6NUAK1CDK1PIK3CD
SCHEMBL15041765 0.76 CDK4 (0.39) CDK4CDK6NUAK1CDK1PIK3CD
SCHEMBL15041640 0.75 CDK4 (0.36) CDK4CDK6NUAK1CDK1PIK3CD
SCHEMBL15041544 0.75 CDK4 (0.39) CDK4CDK6FGFR1CCND1TNK2
SCHEMBL15036177 0.74 PTK2 (0.36) CDK4CDK6NUAK1CDK1PIK3CD
SCHEMBL15041624 0.73 CDK4 (0.38) CDK4CDK6NUAK1CDK1PIK3CD
SCHEMBL15041387 0.73 CDK4 (0.39) CDK4CDK6NUAK1CDK1PIK3CD
SCHEMBL15041732 0.72 FGFR1 (0.39) CDK4CDK6FGFR1CCNA2CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130231348-A1 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-05 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231348-A1 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK3, PAK5 CDK4 408/4885CDK6 299/4885NUAK1 1582/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 CDK4 404/4885CDK6 435/4885NUAK1 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.